Substance / Medication

Niraparib tosylate

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

18 trials linked to this intervention

18
Total Trials
16
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Recommendations for diagnosing STIC: a systematic review and meta-analysis.
Bogaerts Joep M A, Steenbeek Miranda P, van Bommel Majke H D et al. · Virchows Arch · 2022
PMID: 34850262Meta-AnalysisFull text (PMC)
Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis.
Steenbeek Miranda P, van Bommel Majke H D, Bulten Johan et al. · J Clin Oncol · 2022
PMID: 35302882Meta-AnalysisFull text (PMC)
Outcome and Management of Serous Tubal Intraepithelial Carcinoma Following Opportunistic Salpingectomy: Systematic Review and Meta-Analysis.
Ruel-Laliberté Jessica, Kasasni Sara Medina, Oprea Diana et al. · J Obstet Gynaecol Can · 2022
PMID: 36099965Meta-Analysis
Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis.
Cheng Aoshuang, Li Lei, Wu Ming et al. · Eur J Surg Oncol · 2020
PMID: 31521389Meta-Analysis
Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review.
Piedimonte Sabrina, Frank Cairina, Laprise Claudie et al. · Obstet Gynecol · 2020
PMID: 32028491Meta-Analysis

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Niraparib tosylate (substance)
SNOMED CT
1193870006
UMLS CUI
C4476274

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

5
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
18
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.